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Abstract
Background: Oral anticoagulation prevents strokes in patients with atrial fibrillation but, for
reasons that remain unclear, less than 40% of all patients with atrial fibrillation receive warfarin. The
literature postulates that patient and clinician preferences may explain this low utilization.
Design: The proposed research seeks to answer the following questions: i) When assessed
systematically, do patients' and clinicians' preferences explain the utilization of warfarin to prevent
strokes associated with atrial fibrillation? ii) To what extent do patients' and clinicians' treatment
preferences differ? iii) What factors explain any differences that exist in treatment preferences
between patients and clinicians? To answer these questions we will conduct a two-phase study of
patient and clinician preferences for health states and treatments. In the first phase of this study we
will conduct structured interviews to determine their treatment preferences for warfarin vs.
aspirin to prevent strokes associated with atrial fibrillation using the probability trade-off technique.
In the same interview, we will conduct preference-elicitation exercises using the feeling
thermometer to identify the utilities that patients place on taking medication (warfarin and aspirin),
and on having a mild stroke, a severe stroke, and a major bleed. In the second phase of the study
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we will convene focus groups of clinicians and patients to explore their answers to the exercises
in the first phase.
Discussion: This is a study of patient and clinician preferences for health states and treatments.
Because of its clinical importance and our previous work in this area, we will conduct our study in
the clinical context of the decision to use antithrombotic agents to reduce the risk of stroke in
patients with non-valvular chronic atrial fibrillation
Background
Chronic atrial fibrillation (AF) is the commonest sus-
tained cardiac arrhythmia. The prevalence of AF increases
from less than 1% in patients younger than 60 years to
almost 10% in patients over the age of 80 years [1,2]. Sim-
ilarly, the incidence of AF increases from 0.2% per year in
men under the age of 40 years to more than 2% per year
in men aged 80–89 years, with a lower age-adjusted inci-
dence in women [3]. This condition is associated with
substantial mortality and morbidity from stroke, throm-
boembolism and heart failure [4]. On average, 5 out of
every 100 patients will have a stroke every year of whom
3 will have severe disability or die prematurely [5,6]. War-
farin reduces the risk of strokes by 65% [7].
A recent systematic review of practice surveys found that
56 to 85% of patients with atrial fibrillation are not receiv-
ing warfarin [8]. As a result thousands of these patients
will suffer preventable strokes every year and many will be
left with severe and permanent disability or will die pre-
maturely. Why do these patients and their clinicians
choose not to use warfarin? Although this review identi-
fies some system barriers to anticoagulation [8], the most
common reason for not offering and prescribing warfarin
to patients with atrial fibrillation was clinicians' percep-
tion that patients were at high risk of bleeding [9]. This
point suggests that clinicians must consider the majority
of patients with atrial fibrillation to be at sufficiently high
risk of bleeding to warrant withholding warfarin. This
behavior is consistent with clinicians being more bleed-
ing-averse than stroke-averse. The catastrophic impact of
major stroke on patients' lives raises questions about
these apparent values. The wisdom of withholding antico-
agulation is further challenged by data suggesting that cli-
nicians' ability to assess their patients' risk of bleeding on
warfarin is no better than chance [10].
One needs to weigh the benefits of stroke prevention
against the inconvenience and cost of taking warfarin
daily, the inconvenience of periodic blood testing to mon-
itor anticoagulation, and the risk of both minor and
major bleeding. In addition, there are alternatives to war-
farin. Aspirin is less effective than warfarin in avoiding
strokes, it is less likely to cause bleeding [11], and requires
no laboratory testing to monitor its effects. If patients
choose not to take either warfarin or aspirin, they mini-
mize their risk of bleeding and the inconvenience of using
these treatments, but are left with an increased risk of
stroke.
Perhaps patients and clinicians do not choose to use war-
farin because they prefer to avoid the risk of bleeding asso-
ciated with its use. This perspective may be particularly
true for those patients considered at high risk of bleeding.
In this proposal, we will describe a prior study we con-
ducted that suggests that this explanation is unlikely [12].
Our results suggested that patients were much more
stroke-averse than bleeding-averse (Figure 1). On the
other hand, clinicians were less stroke-averse and more
bleeding-averse than the patients. If these results are accu-
rate and widely generalizable, they suggest that warfarin is
underutilized and that the utilization rates are not consist-
ent with patient values but are determined by physician
values. Another way to look at the results involves deter-
mining what participants implied about the relative val-
ues of strokes and bleeds. In effect, clinicians' felt that the
adverse consequences of a severe gastrointestinal hemor-
rhage had more or less the same value (or disutility) as the
adverse consequences of a stroke. This was in spite of
Bleeding thresholds for warfarin [12] Figure 1
Bleeding thresholds for warfarin[12]
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describing that half of the strokes were severe enough to
lead to irreversible major disability or death and of
describing severe gastrointestinal bleeds as transitory
events associated with transfusions, endoscopy, and rela-
tively rapid recovery to pre-morbid function.
If our findings were valid (i.e., they truly reflect individual
patient and clinician choices) and generalizable, they
would have profound implications. First, they suggest that
current clinician behavior of withholding warfarin in
patients at risk of bleeding is inconsistent with the values
and preferences of patients. Second, if clinicians were to
behave in a way consistent with patient preferences,
patients would likely experience fewer strokes thanks to
wider warfarin use. Thus, if confirmed, our findings will
call for interventions to align clinician behavior with
patient preferences.
It is possible, however, that other considerations may
explain our previous findings. First, our previous study
lacked an optimally detailed presentation of warfarin use.
To varying degrees, most decision analyses on the choice
of antithrombotic therapy for atrial fibrillation are sensi-
tive to patients utility for the inconvenience associated
with warfarin administration [13-17], which has been as
low as 0.92 on a 0 to 1.0 scale where 0 is death, and 1.0
full health [18]. Failure to present all the inconveniences
of warfarin use in vivid detail ("unpacked" and described
in its many components) could lead to an underestima-
tion of its relative importance [19].
Second, we did not include consideration of deaths from
all cause and those resulting from bleeding. The literature
does not emphasize the 20% reduction in the risk of dying
associated with warfarin when compared to placebo [7].
There are fewer deaths (although this difference does not
reach statistical significance) among patients using warfa-
rin than among patients using aspirin [11]. However, as
the bleeding risk increases with warfarin (as we will model
during the probability trade-off exercise) the number of
deaths due to bleeding (at most, 10% of severe gastroin-
testinal bleeds will die) will also increase and eventually
offset the small probable mortality benefit of warfarin
over aspirin. We instructed clinicians and patients to con-
sider the scenarios as presented, ignoring other issues that
might come into play in other situation. It is possible,
however, that while patients were easily able to follow
these instructions, clinicians incorporated their knowl-
edge of issues of inconvenience of warfarin use and of
bleeding deaths in their evaluation.
Limitations of our prior study, however, permit alterna-
tive explanations of our findings. In particular, we did not
highlight for patients the inconvenience of warfarin ther-
apy, the risk of death with bleeding, nor the risk of death
with strokes. Discrepancies in clinician and patient
responses may be explained by clinicians taking these fac-
tors into account, while patients did not. The goal of this
proposal is to resolve uncertainty in the interpretation of
our prior study, and deepen our understanding of how cli-
nicians make decisions about warfarin use in patients
with atrial fibrillation. The implications of the study pro-
posed are potentially profound: if differences in clinician
and patient values and preferences underlie the current
apparent underutilization of warfarin, it can be inferred
that there are truly hundreds of thousands of patients
experiencing an unnecessary devastating stroke each year.
Such a result will mandate the development and testing of
interventions to align clinician behavior with patient pref-
erences.
Design
The proposed research seeks to answer the following ques-
tions:
1) When assessed systematically, do patients' and clini-
cians' preferences explain the utilization of warfarin to
prevent strokes associated with atrial fibrillation?
2) To what extent do patients' and clinicians' treatment
preferences differ?
3) What explains any differences in treatment preferences
between patients and clinicians?
To answer these questions we will conduct a two-phase
study of patient and clinician preferences for health states
and treatments. In the first phase of this study we will con-
duct structured interviews with patients and clinicians to
determine their treatment preferences for warfarin vs.
aspirin treatment to prevent strokes associated with atrial
fibrillation. In the second phase of the study we will con-
vene focus groups of patients and clinicians to explore
their answers to the exercises in the first phase. The ethics
committee of the Hospital Sant Pau (Barcelona, Spain)
approved the study.
Setting and target population
Setting
We will conduct this study at three cities in Spain (Barce-
lona, La Coruña and San Sebastian). For each site several
hospitals will collaborate to recruit the required number
of cardiologists and internists. For the recruitment of gen-
eral practicioners we will recruit from the Primary Health
Care areas that belong to these hospitals in each of the
three cities. This multicenter approach will limit the influ-
ence of local views about treatment of atrial fibrillation on
the results of our study and will increase generalizability.BMC Health Services Research 2008, 8:221 http://www.biomedcentral.com/1472-6963/8/221
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Patients
We will enroll patients 60 years of age or older with one
or more of the following conditions: diabetes, hyperten-
sion and history of cardiac disease (heart failure and myo-
cardial infarction). Exclusion criteria include: mini-
mental state examination (MMSE) [20] score < 24, inabil-
ity to complete the research tasks, history of any form of
atrial fibrillation, history of using warfarin (but not of
using aspirin or any other anti-platelet agent since their
use is ubiquitous in the target population), inability to
participate because of illness, or unavailability.
Patients with newly diagnosed atrial fibrillation who are
contemplating the choice of antithrombotic therapy to
prevent strokes represent the ideal patient population.
There are, however, logistical challenges in prospectively
identifying such a group and in ensuring their participa-
tion prior to their making a decision about using or not
using antithrombotic therapy. Not enrolling patients after
they have made a decision regarding anticoagulation is
crucial to prevent bias as a result of cognitive dissonance.
Cognitive dissonance (a state of psychological discomfort
due to inconsistent cognitions) could readily lead patients
to modify their interpretation of information provided
during the study to ensure it was consistent with their pre-
vious decision, a decision that may or may not have been
well-informed [21].
The next best choice is to enroll patients at high risk of
developing atrial fibrillation who may have to make this
choice in the near future. This proximity to the choice
increases the likelihood that patients will view the exercise
as relevant to them and we will obtain meaningful
responses that are reflective of the patients' true prefer-
ences. Thus, the eligible patient will be at high risk of atrial
fibrillation according to data from the Framingham study
[6]. This study identified the following risk factors for
atrial fibrillation: age, hypertension, diabetes, history of
cardiovascular disease, valvular heart disease, and heart
failure. These inclusion and exclusion criteria are broader
than but consistent with eligibility criteria used in our pre-
vious work in which we recruited patients with previous
myocardial infarction or heart failure [12].
Recruitment strategy
We will use several strategies to recruit patients and clini-
cians for this study. In the case of patients we will sample
them from the different databases of the Health Areas
from the three sites where the study will take place. Each
site will provide a random sample of patients fulfilling eli-
gibility criteria for participation. We will invite these
patients to participate initially with a phonecall from their
primary care physician or a delegate from their center. The
study coordinator will follow-up with a phone call to ver-
ify eligibility, obtain verbal consent, and set up an inter-
view date. Patients will give written informed consent to
participate.
We will sample practicing clinicians working in general
medicine (primary care, family medicine, internal medi-
cine) and in cardiology, based in the community or in the
hospitals. Clinicians who spend less than 30% of their
time seeing patients in the outpatient or inpatient settings
or if they have not cared for a patient with atrial fibrilla-
tion in the preceding six months are ineligible to partici-
pate. These eligibility and exclusion criteria should select
clinicians who participate in making decisions about anti-
thrombotic therapy with patients with atrial fibrillation,
the most relevant group for our study. We will send an
electronic letter to clinicians inviting them to participate
in this study. A second mailing will follow if the local
investigator receives no answer. Finally, clinicians who
have not responded to the 2 mailings will receive a phone
call from the local study investigator (a local colleague)
inviting them to enroll.
In our experience, time is the main barrier to clinician par-
ticipation. We plan to complete each clinician interview
within 30 minutes. To achieve this goal, we will use a
highly scripted interview with extreme economy of items.
To ensure the success of the focus groups, we will use mul-
tiple ways to get clinicians to the focus group venue on
time. These include, but are not limited to, sending peri-
odic e-mail reminders, contacting their administrative
assistants to include the focus group on their daily calen-
dars, making same-day reminder phone calls, and arrang-
ing for transportation to the focus group venue, as needed.
First phase: the individual interview
The clinical context of this decision study is the use of
antithrombotic agents to treat chronic non-valvular atrial
fibrillation. Both patients and clinicians will go through
an individual highly scripted interview. To determine
their strength of preference for use of antithrombotic
agents we will conduct a probability trade-off exercise.
This will answer the first research question and will allow
us to determine if there is a difference and if present the
magnitude of the difference in strength of preference for
treatment between patients and clinicians, the second
research question.
To partially answer the third research question (whether
differences in utilities for the relevant health states explain
differences in treatment preferences) we will ask partici-
pants to assign relative value to the relevant health states
using a visual analog scale (also known as the feeling ther-
mometer). The complete elicitation of treatment prefer-
ences and utilities will take approximately 15 minutes.
The patients will receive the mini-mental state examina-
tion and 2 additional "screening" scenarios to gauge theirBMC Health Services Research 2008, 8:221 http://www.biomedcentral.com/1472-6963/8/221
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ability to participate in the probability trade-off exercise.
Thus, we expect patient interviews to take 45 minutes and
clinician interviews to take 30 minutes to complete.
To account for order effects, we will randomize the order
in which participants complete the exercises (probability
trade-off and feeling thermometer) and the health states
within the feeling thermometer (mild stroke, major
stroke, taking warfarin, taking aspirin, severe bleeding).
Clinicians could answer questions thinking about what
they would choose for themselves (if they were to have
atrial fibrillation) or what they would recommend to their
patients. To eliminate this ambiguity (and study this
potential effect), and following the method by Cohen and
Pauker [22], we will randomize clinicians to instructions
that ask them to participate and complete the preference
elicitation tasks in the role of a patient or as a clinician
making a recommendation to a patient.
Prior to the preferences elicitation exercises, patients will
complete a brief questionnaire indicating their age and
gender and whether they have personal knowledge of
someone who had a major or a minor stroke, or a major
gastrointestinal bleed. Likewise, clinicians will indicate
their demographic characteristics, the number of years in
practice, specialty, and experience with atrial fibrillation,
bleeds and strokes.
The health states
The decision to use antithrombotic agents in patients with
atrial fibrillation at risk of stroke involves a choice
between aspirin or warfarin use. "No therapy" is a realistic
option only for the lowest risk patients, or those with a
serious bleeding problem. Decision analyses [23] and
decision support [24] investigators have shown that the
choice of antithrombotic therapy is sensitive to prefer-
ences for the following health states: major and minor
stroke, major gastrointestinal bleed, and taking either
warfarin or aspirin daily (including the need for periodic
monitoring and lifestyle modification with warfarin). We
plan to use the same health state descriptions for stroke
and major bleed that we used in a previous study [12],
which in turn were modified from Man-Son-Hing et al
[25]. These are almost identical to other descriptions in
the literature and have three advantages: (1) have been
published before and were deemed valid to peer investiga-
tors in the field of decision making; (2) have been used
with clinicians for the conduct of a decision study and
therefore were deemed valid and understandable to par-
ticipants similar to those we propose to enroll for the
present study; (3) their use will allow our results to com-
pare to other studies in this field, including our previous
study in a different sample of clinicians.
Probability trade-off
We propose to use the probability trade-off technique to
determine the strength of preference patients and clini-
cians have for antithrombotic use to prevent strokes asso-
ciated with atrial fibrillation. We have described the
conduct of the probability trade-off exercise for the same
decision context [12]. During the interview, the
researcher, following a pre-written script, presents infor-
mation both verbally and visually with the use of colored
pictorial flip charts, known as decision boards (Figure 2).
Participants will review the decision boards describing
major and minor stroke, major bleeding, and inconven-
iences and costs of treatments. After presenting the
descriptions, interviewers will ask participants if the sce-
narios reflect their own appreciation of the issues involved
in the decision and will note any discrepancies. Whatever
their response, we will ask participants to provide
responses assuming that the scenarios represent an accu-
rate and complete characterization of the health states.
This instruction seeks to reduce information asymmetry
between patients and clinicians and between specialists
and generalists. Also, we will use the same decision boards
and the same scripts to interview both patients and clini-
cians. The only difference in the scripts is that clinicians,
when randomized to respond like a clinician making a
recommendation to a patient, would need to indicate
whether they would recommend using warfarin at the
given risks while patients would need to indicate whether
they would use warfarin at the given risks.
During the individual interview, we will present complete
information about the risks, benefits, and inconveniences
of warfarin and aspirin. To demonstrate how we will
determine a patient's threshold for accepting a treatment
we will discuss the scenario for determining the maxi-
mum bleeding increase acceptable for warfarin therapy
(i.e. the bleeding threshold for warfarin) in a comparision
of warfarin vs. aspirin.
The scenario is based on the absolute effects of both drugs
on 100 patients over a two-year period. We will use a
probability trade-off with the elicitation method of "ping-
ponging" to determine participant's thresholds. The inter-
viewer will systematically vary the risk of bleeding with
warfarin (alternating between high and low risk of bleed-
ing) to determine the maximum acceptable increase in the
risk of bleeding with warfarin, given a fixed reduction in
the risk of stroke with warfarin relative to a fixed risk of
bleeding and stroke with aspirin. The alternating presen-
tation of high and low risk of bleeding may reduce "start
point bias" resulting from starting the exercise at the point
of known efficacy and safety of the medications.BMC Health Services Research 2008, 8:221 http://www.biomedcentral.com/1472-6963/8/221
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Given the risk of bleeding with aspirin is two patients in a
hundred (over a two year period) we will offer probabili-
ties from 0 additional bleeds with warfarin to 38 addi-
tional bleeds with the use of two sets of flipcharts (one
exploring up to 17 and one exploring up to 38 additional
bleedings). In our previous study, we compared warfarin
versus no treatment and the mode for patients' bleeding
threshold was 22 additional bleeds per 8 fewer strokes
with warfarin therapy (10.3 [6.1] and 17.4 [7.1] addi-
tional bleeds for physicians and patients respectively)
[12]. The 22 additional bleeds corresponded to the maxi-
mum bleeding threshold explored. Since in this proposal
the number of strokes avoided is 3 (in the comparison of
warfarin versus aspirin), we will increase the range
explored by going up to 38 additional bleeds. Addition-
ally, in the case of participants willing to take warfarin
given an increased risk of an additional 38 bleeds, we will
ask them, without the use of flipcharts, what is the maxi-
mum number of bleeds they would accept before switch-
ing to aspirin (being 100 the maximum). This range
should ensure capturing the preferences of all clinicians
and most patients interviewed.
Initially, participants will complete two eligibility scenar-
ios that compare the outcomes of stroke and bleeding
with two ficticious drugs with the same adverse effects,
burdens and cost, but with major differences in terms of
stroke reduction. If participants do not select the medica-
tion with the higher stroke reduction in both instances
they will be excluded as their choice reflects inadequate
comprehension.
The decision boards will reflect the best available evi-
dence, namely from the meta-analysis of warfarin vs. aspi-
rin for atrial fibrillation [11] (Table 1). Our scenario will
start with a statement of the baseline risk–"with aspirin
treatment there is a baseline risk of a major or minor
stroke over the next two years of 8 patients out of 100 and
a risk of severe bleeding over the next two years of two
patients out of 100. In the case of warfarin there is a base-
line risk of major or minor stroke over the next two years
of 5 patients out of 100". We will then present that risk of
bleeding using a flipchart. In this first flipchart we will
start randomly with either no additional bleedings or with
up to 17 additional bleeds. If the participant decides that
she would still take warfarin with 17 additional bleeds,
with the help of a second flipchart, we will offer up to 38
additional bleeds (starting either at 18 additional bleeds
or at 38 and using the same "ping-ponging" method). In
the case of a patient or physician accepting the 38 addi-
Section of the decision board for probability trade-off [1] comparing outcomes of 2 years of warfarin use vs Figure 2
Section of the decision board for probability trade-off[1]comparing outcomes of2 years of warfarin usevs. aspi-
rin among 100 patients with atrial fibrillation, as used in our preliminary study[12].BMC Health Services Research 2008, 8:221 http://www.biomedcentral.com/1472-6963/8/221
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tional bleeds we will ask her what is the maximum
number of bleeds she would accept before switching to
aspirin.
We will present patients and clinicians with the choice
between warfarin and aspirin use as we think that is the
dominant choice for patients with atrial fibrillation at
average risk of stroke. For a group, perhaps as large as 20%
of patients with atrial fibrillation (i.e., young patients
without hypertension, diabetes, or previous stroke) the
pertinent choice may be between aspirin and no anti-
thrombotic therapy [26]. This group will not be repre-
sented in our intended sample of patients (i.e.,
individuals at risk of atrial fibrillation > 60 years-old, with
hypertension, diabetes, or previous cardiovascular
events). Adding this choice (or the choice of warfarin vs.
no antithrombotic therapy) to the probability trade-off
would require more time than feasible during clinician
interviews. More importantly, the choice between warfa-
rin and aspirin is most likely to demonstrate omission
bias (physicians may place a relatively higher value on
avoiding a bleed than on avoiding a stroke because they
do not witness the strokes they have prevented) or differ-
ences in values and preferences between patients and cli-
nicians, if these were present. Therefore, we will limit the
probability trade-off exercises to the choice of warfarin vs.
aspirin.
The feeling thermometer
To further understand the treatment preferences elicited
using the probability trade-off and capture the values
patients and clinicians place on the health states that may
result from their choice, namely strokes and bleeds, we
will conduct preference-elicitation exercises using the feel-
ing thermometer, a visual analogue scale [27,28]. When
completing the feeling thermometer patients choose the
score on the thermometer that represents the value they
place on the health state they are being asked to evaluate.
The feeling thermometer is anchored at death (0) and per-
fect health (100). The feeling thermometer will allow us
to check understanding of the relative severity of the
health states in question (i.e., patients should assign a
lower value (a value closer to 0) to a major stroke with
severe and permanent disability than a minor stroke).
Because the visual analogue scales may be prone to con-
text bias, that is rating of one state may influence rating of
other states [29,30], we will randomize the order in which
participants will consider the health states to minimize
this bias. We will ask participants to consider the follow-
ing health states one at a time on the feeling thermometer:
▪ Major and minor strokes. We will inform patients that
the sequelae of the stroke will last for the patient's life
expectancy.
▪ Severe bleed. We will inform patients that they will have
a major bleed within the first year of taking the antithrom-
botic agent but will not have another severe bleeding
event for the rest of their life
▪ Taking warfarin
▪ Taking aspirin
Table 1: Summary of results of meta-analysis of warfarin vs. aspirin in patients with atrial fibrillation [11]
Risk % for 2 years
Aspirin* Warfarin Difference between aspirin and warfarin
Stroke
All stroke 7.8 5.0 2.8
Ischemic stroke 7.4 4 3.4
Fatal ischemic stroke 0.925 0.5 0.425
Hemorrhagic stroke 0.4 1.0 -0.6
Fatal hemorrhagic stroke 0.19 0.35 -0.16
Total stroke deaths 1.15 0.85 0.3
All deaths** 10.2 9.4 0.8
Bleeds
EC bleeding*** 2 3.4 -1.4
Fatal EC bleeding 0.175 0.32 -0.145
*, Data correspond to the aspirin alone arms with exclusion of the aspirin + low-dose warfarin arms of the pooled studies; **, including stroke 
deaths, cardiovascular deaths, but not extracranial bleeding deaths; ***, EC = extracranial, mostly severe gastrointestinal bleeds requiring admission 
to hospital, 2 units of blood, or surgery.BMC Health Services Research 2008, 8:221 http://www.biomedcentral.com/1472-6963/8/221
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The second phase: the focus groups
Qualitative research methods are well suited to study per-
sonal meaning, perceptions, beliefs, and values [31].
These methods are therefore appropriate to provide clini-
cians and patients with the opportunity to make explicit
the thinking process, and explore the various hypotheses
suggested as to why participants hold the views they do.
Individual in-depth interviews and focus groups could
provide this information. The individual clinician inter-
views will create an appropriate mindset for participants
to consider in the focus groups why they hold the views
they do. An important advantage of focus groups over in-
depth personal interviews is the opportunity to explore
dynamic interactions among the group members. These
interactions include sharing of ideas and insights, stimu-
lating others to consider the issues that may underlie their
own preferences, and exploring areas of consensus and
dissensus [32].
Thus, the focus groups are most likely to offer plausible
explanations of clinicians' and patients treatment choices
and the reasons for any inconsistency of these choices
with their utilities for the health states of interest. If our
results of the first phase confirm our preliminary findings,
then these explanations will shed light on differences in
preferences between clinicians and patients.
Setting and participants
At each of the 3 sites we will convene focus groups of cli-
nicians and patients. We will follow the recommendation
to keep the focus groups as homogeneous as possible in
terms of preferences regarding the bleeding threshold
[32]. To the extent that group members perceive others
around the table as similar to themselves, they may feel
safe to express themselves while expecting understanding
and respect from the other members. We plan to convene
six focus groups in total (3 of clinicians and 3 of patients).
These numbers relate to our experience with focus groups
and their information yield and to what is feasible for this
proposal. Members of the focus group will be recruited
from phase I to represent different preferences
Group configuration and data collection
Each group will have 10 participants per session, a trained
facilitator (a clinician) and an expert assistant (not a clini-
cian) [32]. The facilitator leads the focus group, facilitates
the group ensuring that all participate, ensures that the
group completes the agenda on time, and monitors and
manages the group dynamic. The assistant (i.e., an expert
qualitative researcher) will participate in all focus groups
at all site and will document seating arrangements, the
first words of each member, take notes on interaction
dynamics and nonverbal behaviors, and operate the tape
recorders. A digital tape recorder (and a backup) equipped
with tabletop microphones will document all acoustic
data for later transcription. The setting will be a small con-
ference room in the hospital or primary care center. We
will pay particular attention to issues related to noise, will
limit interruptions once the focus group dynamic begins,
and will keep the meeting on time. Participants will spend
about 90 minutes discussing the agenda described in the
following section.
Focus group agenda
The goals of the focus group are to educate the members
about the results of the individual interviews, and to
explore why clinicians and patients have the preferences
they do. The facilitator will first ask about this in an open
ended way, allowing participants to express their views in
their own words in order to explore what reasons they
give. Another goal of the focus groups is to get members
to make explicit their thinking process that led to those
preferences, and to explore the various hypotheses sug-
gested (e.g., omission bias, avoidance of clinician-associ-
ated risk) as to why clinicians hold the views they do. The
facilitator will start the proceedings by setting ground
rules, making introductions, and using warm-up exercises
to set a comfortable and open environment for exchange
of ideas.
To achieve the research goals of the focus group, the facil-
itator will guide focus group members through a struc-
tured process: The facilitator will first present results from
the individual interviews. Aggregate data will be presented
and in addition, each participant will receive the results of
their individual responses during the preference elicita-
tion exercises. The facilitator will then elicit member
responses to open-ended questions that he will pose to
the group about these findings. For example, the facilita-
tor will check that group members understand the find-
ings before further discussion. Then, the facilitator will
ask whether group members are surprised about the find-
ings and if so, why or why not. They will be asked to com-
ment on why they hold the particular treatment
preferences expressed in the individual exercises. This will
be followed with more structured elicitation exercises. The
facilitator will contrast the results of the treatment prefer-
ence exercise with the results of the feeling thermometer
exercises to the extent that these exercises reveal, on aver-
age, different apparent values placed upon the health
states. In addition, the following contrasts will be pre-
sented to initiate or continue discussion with the group:
▪ Direct contrast of the choices and strength of preferences
for antithrombotic treatment of the average clinician in
the focus group and of the average patient in the study
(i.e., the number of additional bleeds that clinicians and
patients are willing to tolerate to prevent an additional
stroke at the point of indifference between using warfarin
and using aspirin).BMC Health Services Research 2008, 8:221 http://www.biomedcentral.com/1472-6963/8/221
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▪ Direct contrast of the average utilities for stroke, bleed-
ing, and using antithrombotic agents between patients
and clinicians.
To promote and focus debate the facilitator may ask the
following questions to the group (if appropriate given the
results):
▪ Can you describe, in your own words, the thought proc-
esses you went through in making your decisions during
the probability trade-off and feeling thermomether exer-
cises?
▪ Do you think that your answers to probability trade-off
and feeling thermomether are consistent with each other?
Why or why not?
▪ Which one of the exercises (probability trade-off, feeling
thermomether) do you think captured more accurately
the true relative values you place on avoiding bleeds and
preventing strokes? Why?
Depending on the results during phase 1 (individual
interviews), other questions could be relevant, including
the following:
▪ You placed a relatively higher value on bleeding and a
relatively lower value on stroke when making a decision
(probability trade-off) than when we looked at those out-
comes separately (feeling thermomether). Why?
▪ Can you think of plausible explanations for the differ-
ences between clinicians and patients choices and prefer-
ences for treatment?
▪ Can you think of plausible explanations for the differ-
ences between the answers that clinicians gave when they
participated as patients and when they participated as cli-
nicians?
Analysis plan
Research question 1
When assessed systematically, do patients' and clinicians'
preferences explain the apparent underutilization of war-
farin to prevent strokes associated with atrial fibrillation?
Description of treatment preferences
We will use probability trade-off results to determine the
number of additional bleeds that participants are willing
to tolerate per stroke prevented with warfarin at the point
of switch to aspirin. We will call this variable b. We will
describe the distribution of b in clinicians grouped by age,
gender, years in practice, specialty, experience with atrial
fibrillation, experience with bleeds and strokes, and
whether they participated as clinicians or as patients. We
will also describe b in patients grouped by age and gender,
and by personal knowledge of someone who had a major
or a minor stroke, or a major gastrointestinal bleed. We
will also describe the distribution of b in clinicians and
patients by site. We will conduct exploratory linear regres-
sion analysis using b as the dependent variable and clini-
cian characteristics listed above as the independent
variables. The results of this analysis will guide our
choices for subgroup analyses to answer Research Ques-
tion 2.
Research question 2
To what extent do patients' and clinicians' treatment pref-
erences differ?
Differences in treatment preferences between patients and clinicians
We will test the difference of the means of b between the
patients (bp) and clinicians (bc) using an unpaired t test.
The observed distribution of bp in our preliminary work
was highly skewed. This was because patients clustered at
the highest b offered. For this study, we propose to offer a
maximum  b  that is twice as large as the maximum b
offered in our preliminary study. Furthermore, we will be
studying a relatively large number of patients and clini-
cians with distribution of the means approximating the
normal distribution with SEM = SD/vn. Our sample sizes
will be considerably larger than 30, a size which is often
taken as a guideline threshold, above which the sample
distribution of the sample mean will be reasonably nor-
mally distributed, even if the distribution of individual
values is substantially skewed. Thus, the use of the t-test is
appropriate. However, we will also use the Mann-Whitney
test, a non-parametric test that does not require the
assumption of normality of the distribution. After identi-
fying pertinent subgroups in the analysis to Research
Question 1, we will conduct modified t tests to test the dif-
ference of the means of b between the patients and the
subgroup of clinicians of interest. A modified t  test is
based on the pooled estimate of variance from all the sub-
groups [33]. The resulting P values can be adjusted for
multiple comparisons using the Bonferroni method (mul-
tiplying the resulting P value by the number of paired
comparisons performed).
We will also determine the proportion of patients and cli-
nicians who would choose to take or recommend warfarin
when b = 0.5 (that is, when patients experience one bleed
for every two strokes prevented). We designate this value
of b as bRCT because it is the average number of additional
bleeds per stroke prevented reported in randomized trials
of warfarin vs. aspirin from the meta-analysis [11] (Table
1). We will test the difference in these proportions using
Fisher's exact test and will estimate the exact 95% confi-
dence interval of the odds ratio for the proportions of
patients and clinicians who would use warfarin at bRCT.BMC Health Services Research 2008, 8:221 http://www.biomedcentral.com/1472-6963/8/221
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We will also determine the proportion of clinicians from
pertinent subgroups (identified in Research Question 1)
who would choose to recommend warfarin at bRCT = 0.5.
Then, we will test the differences between this proportion
and the proportion of clinicians not in the subgroup rec-
ommending warfarin when b = 0.5, as well as the differ-
ence between the proportion recommending in the
subgroup and the proportion of patients who would
choose to take warfarin at bRCT.
Research question 3
What explains any differences in treatment preferences
between patients and clinicians?
Differences in utilities between patients and clinicians
In responding to the feeling thermometer, each partici-
pant will provide 5 utilities (for major and minor stroke,
major bleed, using daily aspirin, using daily warfarin). We
will compare the distributions of each of these utilities in
patients and clinicians using the Mann-Whitney test, a
nonparametric test, as these variables are usually highly
skewed. We will also use the t test to test the difference of
the means of the utilities between patients and clinicians.
To evaluate the consistency between participant utilities
for health states and b (that is, the number of additional
bleeds per stroke prevented at the point of switch from
warfarin to aspirin in the probability trade-off exercise) we
will examine scatter plots of each of the utilities and b.
Also, we will estimate the correlations between each of the
utilities for the 5 health states and b. We will conduct lin-
ear regression analysis with b as dependent variable and
with utilities as independent variables. We will attend to
the interaction between the utilities, which we anticipate
being a key issue, in this analysis.
Analysis of focus group data
Data from the 6 focus groups sessions will be transcribed
verbatim and checked for accuracy by comparing the writ-
ten text to each audio tape. Initially, two experienced
researchers in qualitative methods using an editing
approach [34] will work independently to develop a cod-
ing system to identify the major themes from data con-
tained in two of the focus groups transcripts. The
researchers will then meet to compare the consistency and
meaning of the codes developed and their application in
the first set of two transcripts. Based on these results,
researchers will then modify the coding scheme based and
establish an audit trail [35]. Then, the two researchers,
working independently, will code two further focus group
transcripts using the coding scheme and again compare
results, discussing and resolving any disagreements. This
iterative process will continue until researchers finish cod-
ing all the transcripts. The codes (themes) developed will
focus on capturing the kinds of thought processes and
rationales that clinicians used to make their treatment
preferences in the first phase interviews. In the focus
group, clinicians will receive feedback on the results of the
first phase interviews to set the context for the discussion
of reasons for these preferences. The results will include
the distribution of preferences of patients and clinicians,
differences in these distributions, and the degree of inter-
nal consistency between clinicians' treatment preferences
and their utilities for the relevant health states.
Data from focus groups transcripts will be entered into
Atlas.ti http://www.atlasti.com/, a computer friedly soft-
ware program that assists with data management, search,
and retrieval of textual information [35]. Data analysis
will occur at three different levels: description, analysis,
and interpretation [36]. In terms of description, we will
develop a structured form to summarize key information
from each focus group transcript. We will also describe
data segments from the transcripts and code them by
theme. Next, we will undertake a comparative a nalysis of
themes across the six focus groups as a whole to identify
similarities and differences in the data. Finally, we will
identify how participants think about the underlying
thought processes they used to determine their prefer-
ences and point out implications for practice. During the
data analysis and write up stages, we will ask clinicians
from each focus group to review and provide feedback on
the written summary prepared for their specific group in
order to ensure that these summaries accurately reflect the
key themes from the participants' perspective [32,37,38].
Sample size estimation
We require six focus groups, 1 of generalists and 2 of car-
diologists at Barcelona, 1 of generalist at Galicia and País
Vasco. We will undertake 1 group of patiens in each site.
Ideally, each group should have 8 to 10 participants. We
anticipate that not every clinician will be able to partici-
pate. To ensure 8 clinicians per group, we will enroll 12
potential participants per group. We will construct the
focus groups to maximize homogeneity of specialty, expe-
rience with patients with atrial fibrillation, and treatment
preferences during individual interviews (phase 1). From
our survey of faculty at the 3 sites, less than 10% of clini-
cians at each site are not eligible. Therefore we would need
to enroll 20% of eligible clinicians at each site to achieve
our sample size of 96 clinicians which will ensure ade-
quate numbers for the focus groups.
Our study should be powered to determine differences in
means of bp and bc, that is, differences in the treatment
preferences of patients and clinicians, the key variable. In
our previous study, the effect size (difference in mean b
between patients and clinicians) was 0.9 (this is calculated
from sample means (and SDs) of 2.2 (0.9) and 1.3 (0.8)
in the patients and clinicians, respectively). Although it is
not immediately evident what magnitude of the differ-BMC Health Services Research 2008, 8:221 http://www.biomedcentral.com/1472-6963/8/221
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ence in b would be clinically important, readers and com-
mentators have uniformly considered the differences we
showed as important. Table 2 shows the power we would
have with the proposed sample size of 96 clinicians and
an equal number of patients, and also illustrates the lim-
ited impact of increasing the number of patients from 1:1
to 1:3. Therefore, given the number of clinicians available
to us, we will have ≥ 80% power to detect differences in
means ≥ 0.4·SD. We will have ≥ 80% power to detect dif-
ferences in means of bp and bc ≥ 0.75·SD between sub-
groups of ≥ 20 clinicians and 96 patients. In summary,
after enrolling 96 patients and 96 clinicians we will have
≥ 80% power to detect (1) bp - bc > 0.4 SD, (2) odds ratio
≥ 2.6 of the proportion of patients and clinicians with b >
bRCT (if that proportion is 0.63 or smaller among clini-
cians), and (3) a difference in mean utilities of ≥ 0.4 SD.
We need to enroll 96 clinicians to ensure 8 members per
focus group. Enrolling more than 96 patients has a very
small impact on power. Thus, we will recruit 96 patients
and 96 clinicians for this study.
Discussion
Thousands of patients with atrial fibrillation will suffer
preventable strokes this year because they do not receive
anticoagulation. A number of lines of evidence, including
our own prior study, suggest that differences between cli-
nician and patient preferences regarding warfarin versus
alternative management of atrial fibrillation may explain
this apparent underutilization of anticoagulation. If this is
so, development and testing of interventions to increase
rates of anticoagulation in patients with atrial fibrillation
should become a matter of urgency.
The evidence is not, however, strong enough to justify
proceeding confidently with the development and testing
of such interventions. In particular, we have identified
methodological limitations in our prior work that raise
the possibility that a different understanding of the
options presented may explain differences in clinicians
and patients choice. We now propose to repeat our prior
study with a stronger methodology that will allow us to
determine the true explanation of the results. We may find
that, when they understand the options in a similar way,
clinicians and patients make similar choices. If this proves
to be the case, it would suggest that the low rates of anti-
coagulation in patients with atrial fibrillation reflect a
shared aversion to bleeding risk in clinicians and patients.
Such a finding would prompt the conclusion that current
rates of anticoagulation are, in fact, appropriate.
Our review of the evidence suggests that it is more likely
that we will confirm substantially different treatment
choices in clinicians and patients. This result would sug-
gest that current low rates of anticoagulation in atrial
fibrillation reflect clinician and not patient values, and
mandate urgent development and testing of interventions
to increase rates of anticoagulation, and thus prevent
unnecessary strokes. Such findings would not, however,
explain why clinician and patient choices differ. We see
two leading possibilities. One is that, relative to patients,
clinicians experience the post-stroke state as relatively less
aversive, and having a gastrointestinal bleed as relatively
more aversive, than do patients. The second explanation
is that clinicians and patients share the same values for
stroke and bleeding, but the circumstances of clinical deci-
sion-making lead clinicians to make different choices. In
particular, we hypothesize that omission bias associated
with efforts to reduce clinician-generated risk, may
explain the results. This explanation posits that clinicians
put more weight on commission of a behavior that leads
to adverse consequences (bleeding through warfarin
administration) than an omission of behavior that could
lead to beneficial consequences (stroke prevention
through warfarin administration). We will explore this
issue through direct measurement of utilities for stroke
and bleeding, and through focus groups with the partici-
pating clinicians.
On completion of this study, we will hope to achieve
major advances in understanding clinician and patient
decision-making in atrial fibrillation. Our anticipated
results will challenge investigators, medical educators,
and health care providers to develop and test strategies to
deal with differences in clinician and patient choices. Our
results will guide the development of these strategies,
which may include innovations in undergraduate and
post-graduate education, enhancements to the clinical
encounter to facilitate patient-clinician communication
and shared decision-making, increasing use of decision
support tools in clinical practice, and monitoring and
feedback of clinician success in providing optimal antico-
agulation in patients with atrial fibrillation. For example,
our experience using decision boards in this study will
inform the organization and conduct of a randomized
controlled trial to test their efficacy in helping patients
with atrial fibrillation make informed choices.
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